» Articles » PMID: 15164944

Cerebrospinal Fluid S-100 Protein Levels in Neurological Pathologies

Overview
Specialties Biochemistry
Physiology
Date 2004 May 29
PMID 15164944
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

The aim of this paper was to evaluate S-100 concentration in cerebrospinal fluid (CSF) from patients with different neurological disorders, and in subjects with no proven neurological pathology, in order to study possible differences in their protein concentrations. The total number of patient-samples examined was 119 (58 males and 61 females; mean age 35 yrs, 1-79 yrs). Based on the final diagnoses, nine patient groups were studied: a control group, meningitis, acute lymphatic leukemia (ALL), dementia, hydrocephalia, polyneuropathy-motor neuron disease, acute cerebral infarction (ACI), and patients diagnosed with multiple sclerosis. S-100 protein concentrations were measured by the Sangtec 100 two-site immunoradiometric assay. The highest S-100 levels in CSF were found in the dementia group, ACI group, bacterial-fungal and lymphocytic meningitis groups (Kruskal-Wallis test). The S-100 concentrations in these groups were significantly higher compared with the control group (Mann-Whitney U test, p<0.05, p<0.01) and the multiple sclerosis group (p<0.05, p<0.01). No other significant differences were found between groups. Our results suggest that the high protein levels in CSF found in these pathologies may reflect the presence of brain damage. However, the levels need to be considered individually, as they depend on several factors, such as age, severity of brain damage or interval between the onset of brain damage and the taking of the sample.

Citing Articles

Brain injury biomarkers and applications in neurological diseases.

Zhang H, Wang J, Qu Y, Yang Y, Guo Z Chin Med J (Engl). 2024; 138(1):5-14.

PMID: 38915214 PMC: 11717530. DOI: 10.1097/CM9.0000000000003061.


S100B Protein but Not 3-Nitrotyrosine Positively Correlates with Plasma Ammonia in Patients with Inherited Hyperammonemias: A New Promising Diagnostic Tool?.

Czarnecka A, Obara-Michlewska M, Wesol-Kucharska D, Greczan M, Kaczor M, Ksiazyk J J Clin Med. 2023; 12(6).

PMID: 36983411 PMC: 10056255. DOI: 10.3390/jcm12062411.

References
1.
Infante J, Torres-Avisbal M, Martinez A, Vallejo J, Aguilera C, Contreras P . Evaluation of tumor marker S-100 in cerebrospinal fluid from subjects with nonischemic brain pathologies. Tumour Biol. 1999; 21(1):38-45. DOI: 10.1159/000030109. View

2.
Green A, Harvey R, Thompson E, Rossor M . Increased S100beta in the cerebrospinal fluid of patients with frontotemporal dementia. Neurosci Lett. 1997; 235(1-2):5-8. DOI: 10.1016/s0304-3940(97)00701-5. View

3.
Sindic C, Chalon M, Cambiaso C, Laterre E, Masson P . Assessment of damage to the central nervous system by determination of S-100 protein in the cerebrospinal fluid. J Neurol Neurosurg Psychiatry. 1982; 45(12):1130-5. PMC: 491696. DOI: 10.1136/jnnp.45.12.1130. View

4.
Mokuno K, Kato K, Kawai K, Matsuoka Y, Yanagi T, Sobue I . Neuron-specific enolase and S-100 protein levels in cerebrospinal fluid of patients with various neurological diseases. J Neurol Sci. 1983; 60(3):443-51. DOI: 10.1016/0022-510x(83)90155-7. View

5.
Hauschild A, Engel G, Brenner W, Glaser R, Monig H, Henze E . S100B protein detection in serum is a significant prognostic factor in metastatic melanoma. Oncology. 1999; 56(4):338-44. DOI: 10.1159/000011989. View